ArticleResearch and reports in urology2026
Quantitative Morphometric Response to Neoadjuvant Androgen-Deprivation Therapy and Its Prognostic Role After Radical Prostatectomy.
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant Androgen-Deprivation Therapy (Nadt) Prior to Radical Prostatectomy (Rp) Induces Heterogeneous Morphological Responses in Prostate Cancer (Pca). Complete Pathological Response Is Rare, Therefore, Quantitative Assessment of Residual Viable Tumor May Provide Additional Prognostic Information Beyond Conventional Clinicopathological Parameters. Materials and Methods: In this retrospective single-center study conducted between 2015 and 2021, 84 patients with localized and locally advanced PCa treated with NADT followed by RP were analyzed. Residual tumor burden (RTB) and residual tumor area (RTA) were quantified using calibrated digital morphometry. Optimal cut-off values for biochemical recurrence (BCR) were determined using ROC analysis. Biochemical recurrence-free survival (BCRFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards regression models. Results: During a median follow-up of 56 months, 62 BCR events and 12 deaths were observed. ROC analysis identified cut-off values of 32.5% for RTB and 50.5 mm Discussion and conclusion: Quantitative assessment of residual viable tumor following NADT is associated with BCR risk, however, their prognostic impact appears largely driven by intrinsic tumor biology, particularly cribriform architecture and baseline risk stratification. Morphometric assessment may complement postoperative risk evaluation but should not be used as a standalone prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.